Enadenotucirev | |
---|---|
Virus classification | |
(unranked): | Virus |
Realm: | Varidnaviria |
Kingdom: | Bamfordvirae |
Phylum: | Preplasmiviricota |
Class: | Tectiliviricetes |
Order: | Rowavirales |
Family: | Adenoviridae |
Genus: | Mastadenovirus |
Species: | Human mastadenovirus B
|
Enadenotucirev is an investigational oncolytic virus that is in clinical trials for various cancers. [1]
It is an oncolytic A11/Ad3 Chimeric Group B Adenovirus, previously described as ColoAd1. [2]
Enadenotucirev has also been modified with additional genes using the tumor-specific immuno-gene therapy (T-SIGn) platform to develop novel cancer gene therapy agents.[ citation needed]
The T-SIGn vectors at clinical study stage are:[ citation needed]
In Jan 2015 the European Medicines Agency's (EMA) Committee for Orphan Medical Products (COMP) designated enadenotucirev as an orphan medicinal product for the treatment of ovarian cancer. [3]
Two clinical trials have been completed with enadenotucirev. The EVOLVE study [4] and the MOA study. [5]
As of June 2019 [update], there are two active phase 1 trials: OCTAVE (in ovarian cancer) [6] and SPICE (in multiple solid tumor indications) [7]
Of the T-SIGn viruses, NG-350A has an ongoing clinical study. [8]
Enadenotucirev | |
---|---|
Virus classification | |
(unranked): | Virus |
Realm: | Varidnaviria |
Kingdom: | Bamfordvirae |
Phylum: | Preplasmiviricota |
Class: | Tectiliviricetes |
Order: | Rowavirales |
Family: | Adenoviridae |
Genus: | Mastadenovirus |
Species: | Human mastadenovirus B
|
Enadenotucirev is an investigational oncolytic virus that is in clinical trials for various cancers. [1]
It is an oncolytic A11/Ad3 Chimeric Group B Adenovirus, previously described as ColoAd1. [2]
Enadenotucirev has also been modified with additional genes using the tumor-specific immuno-gene therapy (T-SIGn) platform to develop novel cancer gene therapy agents.[ citation needed]
The T-SIGn vectors at clinical study stage are:[ citation needed]
In Jan 2015 the European Medicines Agency's (EMA) Committee for Orphan Medical Products (COMP) designated enadenotucirev as an orphan medicinal product for the treatment of ovarian cancer. [3]
Two clinical trials have been completed with enadenotucirev. The EVOLVE study [4] and the MOA study. [5]
As of June 2019 [update], there are two active phase 1 trials: OCTAVE (in ovarian cancer) [6] and SPICE (in multiple solid tumor indications) [7]
Of the T-SIGn viruses, NG-350A has an ongoing clinical study. [8]